News | Brachytherapy Systems | August 03, 2017

Clinical Data Supports Use of Xoft System for Endometrial Cancer

Preliminary results presented at AAPM 2017 show targeted approach reduces toxicity to organs at risk

Clinical Data Supports Use of Xoft System for Endometrial Cancer

August 3, 2017 — Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of endometrial cancer at the American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition, July 30-Aug. 3 in Denver. iCAD also showcased its multi-platform Xoft System and related suite of products at its booth during the meeting.

Researchers from Miguel Servet University Hospital in Zaragoza, Spain presented preliminary findings from their recent clinical experience treating 36 endometrial cancer patients with electronic brachytherapy using the Xoft System at the AAPM meeting. The dosimetric analysis showed that electronic brachytherapy with the Xoft System delivered a lower dose of radiation to surrounding healthy organs at risk in patients with endometrial cancer, such as the bladder and rectum, than would have been delivered by radiation therapy treatment with Ir-192 or Co-60 sources.

“By precisely targeting cancer cells and sparing surrounding healthy tissue and organs, the Xoft System can successfully treat endometrial cancer while reducing the risk of exposure to surrounding tissue,” said Sergio Lozares, M.D., medical physicist at Miguel Servet University Hospital. “We are encouraged by these early results demonstrating that the Xoft System can be a clinically valuable treatment option for appropriate patients.”

The Xoft System is U.S. Food and Drug Administration (FDA)-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, gynecological cancers and non-melanoma skin cancer.

For more information: www.xoftinc.com

Related Content

DenseBreast-info.org Launches European-Focused Education Coalition
News | Breast Density | February 19, 2018
DenseBreast-info.org (DB-I) announced plans for international expansion with specialized content for Europe and...
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Overlay Init